[
Acar J.F. and F.W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24(Suppl 1): S67–S73.10.1093/clinids/24.Supplement_1.S67
]Search in Google Scholar
[
Bohnert J.A., S. Schuster, E. Fahnrich, R. Trittler, and W.V. Kern. 2007. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND type MDR efflux pump YhiV (MdtF). J. Antimicrob. Chemother. 59: 1216–1222.10.1093/jac/dkl42617062614
]Search in Google Scholar
[
Clinical and Laboratory Standards Institute (CLSI). 2015. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, 3rd ed. CLSI document M31-A3. Clinical and Laboratory Standards.
]Search in Google Scholar
[
Drlica K., X. Zhao, M. Malik and T.K.R. Salz. 2012. Fluoroquinolone resistance: mechanisms, restrictive dosing, and antimutant screening strategies for new compounds, pp. 485–514. In: Dougherty T.J. and M.J. Pucci (eds). Antibiotic Discovery and Development. 1st ed. Springer, US.10.1007/978-1-4614-1400-1_14
]Search in Google Scholar
[
Edgar R. and E. Bibi. 1997. MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J. Bacteriol. 179: 2274–2280.
]Search in Google Scholar
[
Fleige S. and M.W. Pfaffl. 2006. RNA integrity and the effect on the real-time qRT-PCR performance. Mol. Aspects Med. 27: 126–139.10.1016/j.mam.2005.12.00316469371
]Search in Google Scholar
[
Han J.H., I. Nachamkin, P. Tolomeo, X. Mao, W.B. Bilker and E. Lautenbach. 2012. Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli. J. Infect. Dis. 206: 1597–1603.10.1093/infdis/jis567347563822966123
]Search in Google Scholar
[
Jandu N., N.K.L. Ho, K.A. Donato, M.A. Karmali, M. Mascarenhas, S.P. Duffy, C. Tailor and P.M. Sherman. 2009. Enterohemorrhagic Escherichia coli O157:H7 gene expression profiling in response to growth in the presence of host epithelia. PLoS One 4: e4889.10.1371/journal.pone.0004889265485219293938
]Search in Google Scholar
[
Jang W.H., D.H. Yoo and S.W. Park. 2011. Prevalence of and risk factors for levofloxacin-resistant E. coli isolated from outpatients with urinary tract infection. Korean J. Urol. 52: 554–559.10.4111/kju.2011.52.8.554316222221927703
]Search in Google Scholar
[
Johnson L., A. Sabel, W.J. Burman, R.M. Everhart, M. Rome, T.D. MacKenzie, J. Rozwadowski, P.S. Mehler and C.S. Price. 2008. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am. J. Med. 121: 876–884.10.1016/j.amjmed.2008.04.03918823859
]Search in Google Scholar
[
Kallen A.J., H.G. Welch and B.E. Sirovich. 2006. Current antibiotic therapy for isolated urinary tract infections in women. Arch. Intern. Med. 166: 635–639.10.1001/archinte.166.6.63516567602
]Search in Google Scholar
[
Kariuki S., G. Revathi, J. Corkill, J. Kiiru, J. Mwituria, N. Mirza and C.A. Hart. 2007. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams. J. Infect. Dev. Ctries. 1: 257–262.10.3855/jidc.361
]Search in Google Scholar
[
Keeney D., A. Ruzin, F. McAleese, E. Murphy and P.A. Bradford. 2008. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J. Antimicrob. Chemother. 61: 46–5310.1093/jac/dkm397
]Search in Google Scholar
[
Kronvall G. 2010. Antimicrobial resistance 1979–2009 at Karolinska hospital, Sweden: normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development. APMIS 118: 621–639.
]Search in Google Scholar
[
Lomovskaya O. and K.A. Bostian. 2006. Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem. Pharmacol. 71: 910–918.10.1016/j.bcp.2005.12.008
]Search in Google Scholar
[
Magiorakos A.P., A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter and others. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268–281.
]Search in Google Scholar
[
Mohamed Al-Agamy M.H., M.S. El-Din Ashour and I. Wiegand. 2006. First description of CTX-M beta-lactamase-producing clinical Escherichia coli isolates from Egypt. Int. J. Antimicrob. Agents 27: 545–548.10.1016/j.ijantimicag.2006.01.007
]Search in Google Scholar
[
Morgan-Linnell S.K., L. Becnel Boyd, D. Steffen and L. Zechiedrich. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53: 235–241.10.1128/AAC.00665-08
]Search in Google Scholar
[
Nikaido H. and J.M. Pagès. 2012. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36: 340–363.10.1111/j.1574-6976.2011.00290.x
]Search in Google Scholar
[
Oethinger M. and S.B. Levy. 2001. Methods of reducing microbial resistance to drugs. Retrieved from http://www.google.com/patents/CA2378883A1?cl=en, 2016.02.10.
]Search in Google Scholar
[
Oethinger M. and S.B. Levy. 2011. Methods of screening for compounds that reduce microbial resistance to fluoroquinolones. Retrieved from https://www.google.com.ar/patents/US8012711, 2016.02.10.
]Search in Google Scholar
[
Okeke I.N., R. Laxminarayan, Z. a Bhutta, A.G. Duse, P. Jenkins, T.F. O’Brien, A. Pablos-Mendez and K.P. Klugman. 2005. Antimicrobial resistance in developing countries. Part I: Recent trends and current status. Lancet Infect. Dis. 5: 481–493.10.1016/S1473-3099(05)70189-4
]Search in Google Scholar
[
Paterson D.L. 2004. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl 4):S341–S345.10.1086/38269015127367
]Search in Google Scholar
[
Pfaffl M.W., G.W. Horgan and L. Dempfle. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30: e3610.1093/nar/30.9.e3611385911972351
]Search in Google Scholar
[
Poole K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56: 20–5110.1093/jac/dki17115914491
]Search in Google Scholar
[
Rahmati S., S. Yang, A.L. Davidson and E.L. Zechiedrich. 2002. Control of the AcrAB multidrug efflux pump by quorum-sensing regulator SdiA. Mol. Microbiol. 43: 677–685.10.1046/j.1365-2958.2002.02773.x11929524
]Search in Google Scholar
[
Schmitz F.J., A.C. Fluit, M. Lückefahr, B. Engler, B. Hofmann, J. Verhoef, H.P. Heinz, U. Hadding and M.E. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42: 807–810.
]Search in Google Scholar
[
Shaheen H.I., S.B. Khalil, M.R. Rao, R. Abu Elyazeed, T.F. Wierzba, L.F. Peruski Jr., S. Putnam, A. Navarro, B.Z. Morsy and others. 2004. Phenotypic profiles of enterotoxigenic Escherichia coli associated with early childhood diarrhea in rural Egypt. J. Clin. Microbiol. 42: 5588–5595.10.1128/JCM.42.12.5588-5595.200453525915583286
]Search in Google Scholar
[
Singh R., M.C. Swick, K.R. Ledesma, Z. Yang, M. Hu, L. Zechiedrich and V.H. Tam. 2012. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Esche richia coli. Antimicrob. Agents Chemother. 56: 1680–1685.10.1128/AAC.05693-11331831422232279
]Search in Google Scholar
[
Sun J., Z. Deng and A. Yan. 2014. Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations. Biochem. Biophys. Res. Commun. 453: 254–267.
]Search in Google Scholar
[
Swick M.C., S.K. Morgan-Linnell, K.M. Carlson and L. Zechiedrich. 2011. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob. Agents Chemother. 55: 921–924.
]Search in Google Scholar
[
Szabo A., C.M. Perou, M. Karaca, L. Perreard, R. Palais, J.F. Quackenbush and P.S. Bernard. 2004. Statistical modeling for selecting housekeeper genes. Genome Biol. 5: R59.10.1186/gb-2004-5-8-r5950788415287981
]Search in Google Scholar
[
Taylor S., M. Wakem, G. Dijkman, M. Alsarraj and M. Nguyen. 2010. A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines. Methods 50: S1–S5.10.1016/j.ymeth.2010.01.00520215014
]Search in Google Scholar
[
Wagenlehner F.M.E., G. Schmiemann, U. Hoyme, R. Fünfstück, E. Hummers-Pradier, M. Kaase, E. Kniehl, I. Selbach, U. Sester and others. 2011. National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients. Urologe. A. 50: 153–169.10.3238/arztebl.2011.0415313261821776311
]Search in Google Scholar
[
Yang S. 2003. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J. Antimicrob. Chemother. 51: 545–556.
]Search in Google Scholar
[
Yasufuku T., K. Shigemura, T. Shirakawa, M. Matsumoto, Y. Nakano, K. Tanaka, S. Arakawa, S. Kinoshita, M. Kawabata and others. 2011. Correlation of overexpression of efflux pump genes with antibiotic resistance in Escherichia coli strains clinically isolated from urinary tract infection patients. J. Clin. Microbiol. 49: 189–194.10.1128/JCM.00827-10302041921048014
]Search in Google Scholar
[
Yoshihara E. and H. Inoko. 2011. Method or agent for inhibiting the function of efflux pump Pseudomonas aeruginosa. http://www. google.com/patents/US7985410, 2016.02.10.
]Search in Google Scholar
